So, your half empty view has come based on insight from a biz friend who listened to call about and had negative view about trial design? And then couple of oncologist who had negative opinion about the embargoed data?
How would you expect any of these contact to give a reasonable evaluation of a data set that has not been yet made public?
GLTU